All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
An article published in the New England Journal of Medicine described a study evaluating the efficacy of the combination of venetoclax and rituximab in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). The venetoclax-rituximab combination was compared to a combination of bendamustine and rituximab in patients randomly assigned to either treatment. The study was published on 22 March 2018, authored by John F Seymour, Director of the Haematology Department at the Peter MacCallum Cancer Centre, Victoria, Australia, and colleagues.
The authors found that there was significantly higher PFS for R/R CLL patients with venetoclax-rituximab combination than with bendamustine-rituximab. They noted that the difference in response rates assessed by investigators and an independent review committee was due to differing interpretations of residual adenopathy on computed tomographic scans. No new safety signals emerged. The authors concluded that durability of responses would need to be determined to further assess the potential of venetoclax-rituximab therapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox